Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure

Antivir Ther. 1998;3(4):203-7.

Abstract

We examined the in vitro phenotypic and genotypic profiles of an extensively passaged human immunodeficiency virus type 1 clinical isolate which has been selected for lamivudine resistance, with an M184V mutation in a zidovudine-resistant genetic background, and then cultured with zidovudine alone. Our passaging strategy led to a decrease in lamivudine IC50 values, which were comparable to those prior to lamivudine exposure, and the genotypic restoration of the wild-type sequence at codon 184 of reverse transcriptase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Codon
  • Drug Resistance
  • Genotype
  • HIV-1 / drug effects*
  • Humans
  • Lamivudine / pharmacology*
  • Phenotype
  • RNA-Directed DNA Polymerase / genetics
  • Reverse Transcriptase Inhibitors / pharmacology*
  • Virus Replication
  • Zidovudine / pharmacology*

Substances

  • Anti-HIV Agents
  • Codon
  • Reverse Transcriptase Inhibitors
  • Lamivudine
  • Zidovudine
  • RNA-Directed DNA Polymerase